2017
Assessing Feasibility and Acceptability of mHealth among Underserved HIV+ Cocaine Users and Their Healthcare Providers
Brown S, Krishnan A, Ranjit Y, Marcus R, Altice F. Assessing Feasibility and Acceptability of mHealth among Underserved HIV+ Cocaine Users and Their Healthcare Providers. Iproceedings 2017, 3: e48. DOI: 10.2196/iproc.8676.Peer-Reviewed Original ResearchGroup of HIVText remindersCocaine usersDrug treatment clinicsFeasibility of mHealthHIV treatment outcomesSelf-reported cocaine useRisk of transmissionAcceptability of mHealthPhone callsViral suppressionAntiretroviral medicationsMobile medical unitsUnstable living conditionsHIV statusMedication adherenceSubstance use providersTreatment clinicsTreatment outcomesPharmacological interventionsControl trialHIVAdherence behaviorMHealth interventionsHealth behaviors
2009
Pharmacokinetic interactions between buprenorphine/naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxone
Bruce RD, Altice FL, Moody DE, Lin SN, Fang WB, Sabo JP, Wruck JM, Piliero PJ, Conner C, Andrews L, Friedland GH. Pharmacokinetic interactions between buprenorphine/naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxone. Drug And Alcohol Dependence 2009, 105: 234-239. PMID: 19726139, PMCID: PMC2779257, DOI: 10.1016/j.drugalcdep.2009.07.007.Peer-Reviewed Original ResearchConceptsTPV/rBuprenorphine/naloxonePharmacokinetic interactionsBuprenorphine/naloxone therapySteady-state pharmacokinetic evaluationOpioid replacement therapyHIV-negative subjectsHIV-seronegative subjectsOpioid withdrawal symptomsHistorical control subjectsTipranavir/ritonavirConcentration-time profilesRTV levelsAntiretroviral medicationsDosage modificationNaloxone therapyTreatment medicationsOpioid dependenceReplacement therapyWithdrawal symptomsControl subjectsPharmacokinetic effectsHIV therapyPharmacokinetic evaluationNLX
2008
Pharmacokinetic drug interactions between drugs of abuse and antiretroviral medications: implications and management for clinical practice
Bruce RD, Altice FL, Friedland GH. Pharmacokinetic drug interactions between drugs of abuse and antiretroviral medications: implications and management for clinical practice. Expert Review Of Clinical Pharmacology 2008, 1: 115-127. PMID: 24410515, DOI: 10.1586/17512433.1.1.115.Peer-Reviewed Original ResearchPharmacokinetic drug interactionsDrugs of abuseDrug interactionsAntiretroviral therapyHIV treatmentActive illicit drug useClinical implicationsImportant pharmacokinetic drug interactionsClinical case seriesImportant clinical consequencesIllicit drug useHIV/AIDSMetabolism of drugsPharmacokinetic interaction studyAntiretroviral medicationsCase seriesTreatable diseaseClinical consequencesClinical practiceDrug useMedical consequencesSubstance abuseTherapyDrugsAbuse
2007
Integration and co-location of HIV/AIDS, tuberculosis and drug treatment services
Sylla L, Bruce RD, Kamarulzaman A, Altice FL. Integration and co-location of HIV/AIDS, tuberculosis and drug treatment services. International Journal Of Drug Policy 2007, 18: 306-312. PMID: 17689379, PMCID: PMC2696234, DOI: 10.1016/j.drugpo.2007.03.001.Peer-Reviewed Original ResearchConceptsInjection drug useSubstance use treatmentDrug usersEffective substance use treatmentTraining Community Health WorkersActive injection drug useUse treatmentIntegrated care delivery systemSpecialist care providersAdverse drug eventsCommunity health workersComplex patient populationInjection drug usersAdverse side effectsDrug treatment servicesDrug-drug interactionsDetection of tuberculosisCare delivery systemHIV/AIDSAntiretroviral medicationsMedication adherencePatient populationDrug eventsHIV epidemicHealth workers
2006
Pharmacokinetic Drug Interactions Between Opioid Agonist Therapy and Antiretroviral Medications
Bruce RD, Altice FL, Gourevitch MN, Friedland GH. Pharmacokinetic Drug Interactions Between Opioid Agonist Therapy and Antiretroviral Medications. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2006, 41: 563-572. PMID: 16652030, DOI: 10.1097/01.qai.0000219769.89679.ec.Peer-Reviewed Original ResearchConceptsPharmacokinetic drug interactionsOpioid agonist therapyDrug interactionsAgonist therapyAntiretroviral therapyAntiretroviral medicationsImportant pharmacokinetic drug interactionsClinical case seriesImportant clinical consequencesClass of agentsHIV/AIDSPharmacokinetic interaction studyAntiretroviral agentsCase seriesOpioid dependenceHIV treatmentTreatable diseaseHIV therapyClinical consequencesFollowing keywordsMethadoneTherapyClinical implicationsLanguage articlesMedications